You are here : Home / All Sectors / Healthcare / Pharmaceuticals & Drugs / SUVEN PHARMACEUTICALS

SUVEN PHARMACEUTICALS
Intrinsic Value | Fundamental Analysis

Returns | 1W : 1.1% , 1M : 10.3%,1Y : 235.7%
BOM : 543064     NSE : SUVENPHAR    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward
Pledged Shares : None or < 25%
May 18,2021
Price(EOD): Rs. 535.45
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
MarketCap: Rs. 13,632.56 Cr
Stock Market Investing Simplified- The best Video Course by Smart-Investing.in

Check out Industry Peers

Peers & Returns1W1M1Y
SUVEN PHARMACEUTICALS 1.1% 10.3% 235.7%
SUN PHARMACEUTICAL INDUSTRIES -2.4% 9.2% 50.7%
DR REDDYS LABORATORIES -1.5% 7.7% 40.7%
DIVIS LABORATORIES -1.9% 5.7% 70.9%
CIPLA -0.7% -3.3% 54.7%
BIOCON -0.7% -4.8% 15%
AUROBINDO PHARMA -2.5% 9.9% 50.5%
LUPIN -0.9% 13.1% 37.8%
TORRENT PHARMACEUTICALS 0.3% 6.1% 14.8%


FUNDAMENTAL ANALYSIS OF SUVEN PHARMACEUTICALS

 
Fundamentals Score
[Last Annual Data : Mar2020 | TTM
Trailing Twelve Months (TTM) is calculated using last 4 quarterly data and is a good substitute to track Annual results.
Learn More
]
Show Me the Stocks with Fundamentals better than SUVEN PHARMACEUTICALS Premium


VALUATION OF SUVEN PHARMACEUTICALS

 
Valuation Score
Ratio Standalone
P/E
P/B
P/S
25.23
P/E Calculated based on EPS of 21.22
[ Mar2020 - Standalone Results ]

8.71
P/B Calculated based on Book Value of 61.5
[ Mar2020 - Standalone Results ]

17.06
P/S Calculated based on Revenues of 799.094 Cr
[ TTM - Standalone Results ]

Show Me the Stocks with Valuation better than SUVEN PHARMACEUTICALS Premium


FAIR VALUE OF SUVEN PHARMACEUTICALS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
483%
NA (-ve EV)
454%

SHARE PRICE MOMENTUM OF SUVEN PHARMACEUTICALS

DEBT

Year Debt/Equity ratio
Standalone Consolidated
2020
2019
2018
Avg_3yrs
0.24
0.14
-
0.13
0.22
0.14
-
0.12
[Last Annual Data : Mar2020]

PLEDGED SHARES

Pledged Shares
0 %
As on : Mar2021

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad

QTRLY RESULTS

Standalone Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
15.82%
40.27%
49.29%
49.45%
53.85%
73.63%
83.23%
87.77%
QtrlyTrend
8
Latest Qtr: Dec2020

SUVEN PHARMACEUTICALS related INDICES

BSE Indices1W1M1Y
S&P BSE 250 LARGEMIDCAP 1.6% 4.6% 66.7%
S&P BSE 500 1.6% 4.9% 69.2%
S&P BSE ALLCAP 1.5% 5.2% 70.6%
S&P BSE MIDSMALLCAP 1.2% 8.3% 96.1%
S&P BSE 400 MIDSMALLCAP 1.1% 7.9% 96.3%
S&P BSE 150 MIDCAP 1.1% 7% 88.6%
S&P BSE SMALL CAP 1.1% 9.9% 110.7%
S&P BSE HEALTHCARE -1.6% 6.9% 59.5%
NSE Indices1W1M1Y
NIFTY 500 1.6% 4.9% 68.6%
NIFTY MIDCAP150 1.2% 6.8% 88.3%
NIFTY MID SMALL400 1.1% 8% 97.4%

FAQ [Frequently Asked Questions]


Is SUVENPHAR good for long term investment?

As on 18-May-2021, the Fundamentals of SUVENPHAR are Strong and hence it's good for long term investment! See Financial Performance of SUVEN PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is SUVENPHAR UnderValued or OverValued?

As on 18-May-2021, SUVENPHAR is Over Valued and hence NOT a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of SUVENPHAR ?

As on 18-May-2021, the Intrinsic Value of SUVENPHAR is Rs. 94.26 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 91.84
Fair Value [Median EV / Sales Model] : Rs. -6.45
Fair Value [Median Price / Sales Model] : Rs. 96.67
Median Fair Value of SUVENPHAR : Rs. 94.26

Is SUVENPHAR trading at a Premium or Discount?

As on 18-May-2021, SUVENPHAR is trading at a Premium of 468% based on the Median Intrinsic Value!

Is it right time to buy SUVENPHAR shares?

As on 18-May-2021, SUVENPHAR is Over Valued and hence NOT a good buying opportunity according to Share Valuation at this time!

What is the Financial Performance of Industry Peers of SUVENPHAR?

Check out Financials of Industry Peers using below links:
Financials of SUN PHARMACEUTICAL INDUSTRIES LTD
Financials of DR REDDYS LABORATORIES LTD
Financials of DIVIS LABORATORIES LTD
Financials of CIPLA LTD
Financials of BIOCON LTD
Financials of AUROBINDO PHARMA LTD
Financials of LUPIN LTD
Financials of TORRENT PHARMACEUTICALS LTD
Financials of CADILA HEALTHCARE LTD
Financials of ABBOTT INDIA LTD

What are the Frequent Comparisons with SUVENPHAR?

SUVEN PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DR REDDYS LABORATORIES LTD
SUVEN PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD
SUVEN PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD
SUVEN PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs BIOCON LTD
SUVEN PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs AUROBINDO PHARMA LTD
SUVEN PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs LUPIN LTD
SUVEN PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs TORRENT PHARMACEUTICALS LTD
SUVEN PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs CADILA HEALTHCARE LTD
SUVEN PHARMACEUTICALS LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs ABBOTT INDIA LTD

Open Demat Account & Start Investing
    Affiliate Links

Disclosure

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].


All Stocks : A - Z

ALL   A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z